⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448807 | 0.55 | — | — | |
| SCHEMBL334632 | 0.55 | — | — | |
| SCHEMBL166404 | 0.50 | — | — | |
| SCHEMBL726879 | 0.45 | CES1 (0.39) | — | |
| SCHEMBL21952429 | 0.42 | CES1 (0.67) | — | |
| SCHEMBL1995763 | 0.38 | — | — | |
| SCHEMBL28219 | 0.34 | — | — | |
| SCHEMBL10597056 | 0.31 | HDAC8 (0.50) | — | |
| SCHEMBL67142 | 0.31 | — | — | |
| SCHEMBL10066089 | 0.27 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 656 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | claimed |
| WO-2023049060-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | claimed |
| US-20210130321-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-05-06 | — | — | US | claimed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | claimed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| US-9493441-B2 | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | claimed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | claimed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| US-8962608-B2 | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | claimed |
| US-20140243309-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | claimed |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | INTERVET INC. | 2014-08-21 | — | — | US | claimed |
| US-20140228358-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| EP-2106260-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | Verva Pharmaceuticals Ltd (AU) | 2009-10-07 | — | — | EP | claimed |
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | claimed |
| WO-2008089521-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD (AU) | 2008-07-31 | — | — | WO | claimed |
| EP-1768957-A2 | INDOLE-2-CARBOXYLIC ACID HYDRAZIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | Prosidion Ltd. (GB) | 2007-04-04 | — | — | EP | claimed |
| WO-2005085194-A2 | INDOLE-2-CARBOXYLIC ACID HYDRAZIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PROSIDION LIMITED (GB) | 2005-09-15 | — | — | WO | claimed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239785-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-5-(1-PIPERIDIN-4-YL)ISOINDOLINE-1,3-DIONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024137548-A2 | INHIBITORS OF JAK2 | Llydaw Therapeutics, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024129395-A1 | BTK INHIBITORS | GWYNANT THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240199606-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-12006332-B2 | Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION | 2024-06-06 | — | — | US | disclosed |
| US-20240174661-A1 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | VENTUS THERAPEUTICS U.S., INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240174668-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U.S., INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024107658-A2 | INHIBITORS OF TYK2 | VYRNWY THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240158396-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024100046-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100040-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024100044-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024097721-A1 | TARGETING ALLOSTERIC AND ORTHOSTERIC POCKETS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097172-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097989-A1 | RET-LDD PROTEIN DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097980-A1 | RET-LDD PROTEIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024092274-A2 | ENDOCYTIC AGENTS | BIOVENTURES, LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023107968-A9 | FUNCTIONALIZED CYCLODEXTRIN MONOMER AND POLYMER FOR WATER REMEDIATION | NORTHWESTERN UNIVERSITY (US) | 2024-05-02 | — | — | WO | disclosed |
| US-11965042-B2 | Charge-bearing cyclodextrin polymeric materials and methods of making and using same | CYCLOPURE, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4351558-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | Ness Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-04-11 | — | — | US | disclosed |
| WO-2024077298-A1 | DURABLE GRAPHENE OXIDE MEMBRANES COMPRISING FUNCTIONALIZED SUPPORT COMPONENTS | VIA SEPARATIONS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4347040-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF CANCER | Petra Pharma Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024068926-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2024-04-04 | — | — | WO | disclosed |
| EP-3924055-B1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| US-20240092795-A1 | PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-21 | — | — | US | disclosed |
| US-11932650-B2 | Potent agelastatin derivatives as modulators for cancer invasion and metastasis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240083901-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | NOVO NORDISK HEALTH CARE AG (CH) | 2024-03-14 | — | — | US | disclosed |
| EP-4335512-A2 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HiberCell, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333984-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334312-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4331668-A2 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11919902-B2 | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240058341-A1 | SHP2 Inhibitor Compositions and Methods for Treating Cancer | Revolution Medicines, Inc. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240051948-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORP (US) | 2024-02-15 | — | — | US | disclosed |
| US-20240051954-A1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| EP-4320102-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | Ventus Therapeutics U.S., Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20240043424-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2024030968-A1 | COMPOUNDS FOR MODULATING RET PROTEIN | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11891365-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4308092-A1 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11878970-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4304588-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306111-A2 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4302834-A2 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230416209-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | HEALTH RESEARCH INC (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023245162-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245166-A2 | COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| EP-3571187-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH INC (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023220715-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220572-A1 | PTPN2 INHIBITORS | NESS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4274830-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | Theseus Pharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230357216-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2023-11-09 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4267564-A1 | INDOLE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | Novartis AG (CH) | 2023-11-01 | — | — | EP | disclosed |
| EP-4267571-A1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | Novartis AG (CH) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230332104-A1 | ZBTB32 INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-10-19 | — | — | US | disclosed |
| US-11787803-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023196720-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3724189-B1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023183275-A1 | HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4247324-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | Health Research, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230279158-A1 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME | AVENUE GLOBAL DISLOCATION OPPORTUNITIES FUND, L.P. AND AVENUE GLOBAL OPPORTUNITIES MASTER FUND, L.P. | 2023-09-07 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| WO-2023164175-A2 | PROTACS OF MALT1 | TEGID THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11739096-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739071-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739093-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023155710-A1 | IKZF2 DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 苏州国匡医药科技有限公司 | 2023-08-24 | — | — | WO | disclosed |
| EP-4230623-A2 | PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230249137-A1 | FILTRATION APPARATUS CONTAINING ALKYLATED GRAPHENE OXIDE MEMBRANE | JPMORGAN CHASE BANK, N.A. | 2023-08-10 | — | — | US | disclosed |
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3820574-B1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230234981-A1 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2023-07-27 | — | — | US | disclosed |
| US-11702412-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023129553-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-11692065-B2 | Phenazine copolymers and uses thereof | CORNELL UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023118319-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20230203032-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| EP-4200286-A1 | COMPOUNDS AND METHODS OF MODULATING 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | Metrea Biosciences, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107968-A2 | FUNCTIONALIZED CYCLODEXTRIN MONOMER AND POLYMER FOR WATER REMEDIATION | NORTHWESTERN UNIVERSITY (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11673896-B2 | Pyridine compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673901-B2 | Polycyclic compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230173435-A1 | DURABLE GRAPHENE OXIDE MEMBRANES | VIA SEPARATIONS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4188549-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| EP-3532479-B1 | AMIDE COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEV LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2023094965-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-06-01 | — | — | WO | disclosed |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4183782-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DI ONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-11649242-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2023081441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230147285-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143583-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2023079142-A2 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4168007-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | Novartis AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11634435-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-20230124248-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023064164-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-4165169-A1 | ZBTB32 INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023056407-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-3672949-B9 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023049060-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230096175-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3571189-B1 | PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| WO-2023043630-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | NOVARTIS PHARMA AG (CH) | 2023-03-16 | — | — | US | disclosed |
| US-20230070338-A1 | SHP2 Inhibitor Dosing and Methods of Treating Cancer | Revolution Medicines, Inc. (US) | 2023-03-09 | — | — | US | disclosed |
| US-11596633-B2 | SHP2 inhibitor compositions and methods for treating cancer | Revolution Medicines, Inc. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| EP-4126851-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | Petra Pharma Corporation (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11555039-B2 | Amide compounds as kinase inhibitors, compositions and methods of treatment | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2023-01-17 | — | — | US | disclosed |
| WO-2023278483-A1 | COMPOUNDS HAVING 1H-PYRAZOLO[4,3-C]PYRIDIN-6-AMINOS AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535635-B2 | — | — | 2022-12-27 | — | — | US | disclosed |
| EP-3672949-B1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022261145-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | NESS THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022235575-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220306672-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220235055-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20220218722-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-07-14 | — | — | US | disclosed |
| WO-2022150384-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | THESEUS PHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022137085-A1 | INDOLE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | NOVARTIS AG (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022137082-A1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | NOVARTIS AG (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204461-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220194952-A1 | TETRAPYRROLIC CONJUGATES AND USES THEREOF FOR IMAGING | HEALTH RESEARCH, INC. | 2022-06-23 | — | — | US | disclosed |
| EP-4015514-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0]HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220169647-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022109469-A1 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | HEALTH RESEARCH, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220153931-A1 | PHENAZINE COPOLYMERS AND USES THEREOF | CORNELL UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| EP-3724191-B9 | 5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220143183-A1 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | NEW YORK UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11292791-B2 | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3969158-A1 | FILTRATION APPARATUS CONTAINING GRAPHENE OXIDE MEMBRANE | Via Separations, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220073452-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022040324-A1 | COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3954684-A1 | PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220040331-A1 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | AMRYT RESEARCH LIMITED (IE) | 2022-02-10 | — | — | US | disclosed |
| US-11242337-B2 | Compounds useful for treating gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-02-03 | — | — | US | disclosed |
| US-20220033392-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2022-02-03 | — | — | US | disclosed |
| EP-3724191-B1 | 5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES INC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11230546-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20220017645-A1 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME | AVENUE GLOBAL DISLOCATION OPPORTUNITIES FUND, L.P. AND AVENUE GLOBAL OPPORTUNITIES MASTER FUND, L.P. | 2022-01-20 | — | — | US | disclosed |
| EP-3932914-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021260528-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2021-12-30 | — | — | WO | disclosed |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3924418-A1 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME | Cyclopure, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3924054-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021252920-A1 | ZBTB32 INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| US-20210370242-A1 | FILTRATION APPARATUS CONTAINING GRAPHENE OXIDE MEMBRANE | VIA SEPARATIONS, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3390382-B1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-11185537-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-11-30 | — | — | US | disclosed |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210354094-A1 | DURABLE GRAPHENE OXIDE MEMBRANES | VIA SEPARATIONS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| WO-2021222147-A1 | HETEROCYCLIC GCN2 MODULATORS | HIBERCELL, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3902566-A1 | METHODS FOR FORMING POLYPLEXES | Amryt Genetics Ltd. (IE) | 2021-11-03 | — | — | EP | disclosed |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| EP-3897637-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-11155646-B2 | Charge-bearing cyclodextrin polymeric materials and methods of making and using same | CYCLOPURE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210323978-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3292116-B1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0]HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210317136-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210309685-A1 | AMINO ACID SALTS OF NICOTINIC ACID MONONUCLEOTIDE AND NICOTINAMIDE MONONUCLOETIDE AS ANTI-AGEING AGENTS | LIFE BIOSCIENCES INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309686-A1 | QUATERNARY AMMONIUM SALTS OF NICOTINIC ACID AND NICOTINAMIDE MONONUCLOETIDES AND RIBOSIDES AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2021-10-07 | — | — | US | disclosed |
| US-20210309638-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| WO-2021202964-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | PETRA PHARMA CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20210300927-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210292337-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-09-23 | — | — | US | disclosed |
| US-11123694-B2 | Filtration apparatus containing graphene oxide membrane | VIA SEPARATIONS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11117883-B2 | Benzimidazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210253600-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| EP-3864070-A2 | COMPOSITIONS AND METHODS FOR TRANSFECTING CELLS | Amryt Genetics Ltd. (IE) | 2021-08-18 | — | — | EP | disclosed |
| US-11091482-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210246143-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | NOVO NORDISK HEALTH CARE AG, (CH) | 2021-08-12 | — | — | US | disclosed |
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3504205-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210230208-A1 | INORGANIC SALTS OF NICOTINAMIDE MONONUCLOETIDE AS ANTI-AGING AGENTS | LIFE BIOSCIENCES INC (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3851434-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | Genentech, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210206755-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-07-08 | — | — | US | disclosed |
| US-11053218-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-07-06 | — | — | US | disclosed |
| US-20210196742-A1 | AMINO ACID SALTS OF NICOTINIC ACID RIBOSIDES AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2021-07-01 | — | — | US | disclosed |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-06-24 | — | — | US | disclosed |
| US-11040985-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3829715-A1 | QUATERNARY AMMONIUM SALTS OF NICOTINIC ACID AND NICOTINAMIDE MONONUCLOETIDES AND RIBOSIDES AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2021-06-09 | — | — | EP | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-20210163631-A1 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME | AVENUE GLOBAL DISLOCATION OPPORTUNITIES FUND, L.P. AND AVENUE GLOBAL OPPORTUNITIES MASTER FUND, L.P. | 2021-06-03 | — | — | US | disclosed |
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | Revolution Medicines, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-11014927-B2 | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | FORMA THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3820574-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | Novartis AG (CH) | 2021-05-19 | — | — | EP | disclosed |
| US-11001645-B2 | Charge-bearing cyclodextrin polymeric materials and methods of making and using same | CYCLOPURE, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001580-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210130321-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10988441-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988450-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10981915-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210101870-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-04-08 | — | — | US | disclosed |
| EP-3799872-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10968246-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | ARDELYX, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210094956-A1 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3797110-A1 | AMINO ACID SALTS OF NICOTINIC ACID RIBOSIDES AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2021-03-31 | — | — | EP | disclosed |
| WO-2021053555-A1 | GLUE DEGRADERS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3794005-A1 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2021-03-24 | — | — | EP | disclosed |
| EP-3794011-A1 | AMINO ACID SALTS OF NICOTINIC ACID MONONUCLEOTIDE AND NICOTINAMIDE MONONUCLEOTIDE AS ANTI-AGEING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2021-03-24 | — | — | EP | disclosed |
| EP-3794006-A1 | INORGANIC SALTS OF NICOTINAMIDE MONONUCLEOTIDE AS ANTI-AGING AGENTS, ESPECIALLY FOR INFERTILITY TREATMENT | Jumpstart Fertility Pty Ltd (AU) | 2021-03-24 | — | — | EP | disclosed |
| US-20210061841-A1 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | LIFE BIOSCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3784226-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20210053977-A9 | POTENT AGELASTATIN DERIVATIVES AS MODULATORS FOR CANCER INVASION AND METASTASIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-25 | — | — | US | disclosed |
| US-10927130-B2 | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20210047335-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT LLC | 2021-02-18 | — | — | US | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20210009538-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009539-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2021-01-14 | — | — | US | disclosed |
| US-20210009540-A1 | 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-12-31 | — | — | US | disclosed |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2020257253-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257271-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3071203-B1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10870645-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200392162-A1 | CHROMENOPYRIMIDINE DERIVATIVES AS PHOSPHATIDYLINSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200392156-A1 | AMINOPYRIMIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2020-11-26 | — | — | US | disclosed |
| EP-3313397-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200360869-A1 | DURABLE GRAPHENE OXIDE MEMBRANES | JPMORGAN CHASE BANK, N.A. | 2020-11-19 | — | — | US | disclosed |
| US-20200360868-A1 | FILTRATION APPARATUS CONTAINING GRAPHENE OXIDE MEMBRANE | JPMORGAN CHASE BANK, N.A. | 2020-11-19 | — | — | US | disclosed |
| WO-2020232395-A1 | FILTRATION APPARATUS CONTAINING GRAPHENE OXIDE MEMBRANE | VIA SEPARATIONS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232398-A1 | DURABLE GRAPHENE OXIDE MEMBRANES | VIA SEPARATIONS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-10836741-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10829461-B2 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2020223174-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10822316-B2 | 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3728217-A1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728228-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728230-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200331913-A1 | ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331847-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2020-10-22 | — | — | US | disclosed |
| EP-3724191-A1 | 5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1 -YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | Pyramid Biosciences, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10807976-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020205796-A1 | PHENAZINE COPOLYMERS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2020198361-A1 | TETRAPYRROLIC CONJUGATES AND USES THEREOF FOR IMAGING | HEALTH RESEARCH, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200262936-A1 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME | AVENUE GLOBAL DISLOCATION OPPORTUNITIES FUND, L.P. AND AVENUE GLOBAL OPPORTUNITIES MASTER FUND, L.P. | 2020-08-20 | — | — | US | disclosed |
| WO-2020165833-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168104-A1 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME | CYCLOPURE, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-3696181-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3692028-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | Forma Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10738007-B2 | Amide compounds as kinase inhibitors, compositions and methods of treatment | Translation Drug Development, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-3681881-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3681885-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3680241-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Forma Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200216445-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2020140116-A1 | METHODS FOR FORMING POLYPLEXES | AMRYT GENETICS LTD (IE) | 2020-07-02 | — | — | WO | disclosed |
| EP-3672949-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2020128972-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020110009-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10654883-B2 | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents | Jumpstart Fertility Pty Ltd (AU) | 2020-05-19 | — | — | US | disclosed |
| US-10647701-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-12 | — | — | US | disclosed |
| US-10640489-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2020-04-23 | — | — | US | disclosed |
| EP-3377493-B1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10611750-B2 | Tetrahydroquinoline compositions as bet bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20200087280-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2020-03-19 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10590090-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200079776-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20200079744-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20200069643-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | NOVO NORDISK HEALTH CARE AG, (CH) | 2020-03-05 | — | — | US | disclosed |
| EP-3483164-B1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | FORMA THERAPEUTICS INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200062795-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200062771-A1 | POTENT AGELASTATIN DERIVATIVES AS MODULATORS FOR CANCER INVASION AND METASTASIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2020-02-20 | — | — | US | disclosed |
| EP-3472131-B1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20200048212-A1 | 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200048211-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2020028682-A1 | QUATERNARY AMMONIUM SALTS OF NICOTINIC ACID AND NICOTINAMIDE MONONUCLOETIDES AND RIBOSIDES AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2020-02-06 | — | — | WO | disclosed |
| US-20200039958-A1 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2020028684-A1 | SALTS OF NICOTINIC ACID AND NICOTINAMIDE AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2020-02-06 | — | — | WO | disclosed |
| EP-3071205-B1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020012337-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-10513508-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-24 | — | — | US | disclosed |
| US-10508077-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-10501424-B2 | 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-10494352-B2 | 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-03 | — | — | US | disclosed |
| US-10494351-B2 | 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-03 | — | — | US | disclosed |
| US-10494353-B2 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-12-03 | — | — | US | disclosed |
| US-20190352325-A1 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2019-11-21 | — | — | US | disclosed |
| US-20190352298-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2019-11-21 | — | — | US | disclosed |
| US-10479772-B2 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190345149-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3565808-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3565811-A1 | INHIBITORS OF NHE-MEDIATED ANTIPORT | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10472337-B2 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190337965-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3240791-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10464910-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464909-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190330233-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10457652-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3555066-A1 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3555090-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10450283-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450284-B2 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3414251-B1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10442776-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190308980-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308973-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3548479-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD Pharmaceuticals, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10421731-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421732-B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10414738-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414755-B2 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2019-09-17 | — | — | US | disclosed |
| US-10407418-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407419-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3532479-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS | Translational Drug Development, LLC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10399980-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10392413-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | ARDELYX, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190248744-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS AND METHODS OF TREATMENT | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-08-15 | — | — | US | disclosed |
| US-10377773-B2 | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377767-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377726-B2 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190241506-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO HEALTH, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3154976-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10351571-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| EP-3448859-B1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | FORMA THERAPEUTICS INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2019118584-A1 | 5-(2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1 -YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER | PYRAMID BIOSCIENCES, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-3483164-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Forma Therapeutics, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190127339-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-05-02 | — | — | US | disclosed |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190119234-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119230-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119231-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119227-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119235-A1 | 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119229-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119233-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119228-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-25 | — | — | US | disclosed |
| US-20190119232-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10266487-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190112282-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112279-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112284-A1 | 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112283-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112281-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2019071073-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190092762-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10239845-B2 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2019055808-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019055877-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20190071422-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2019-03-07 | — | — | US | disclosed |
| US-20190071418-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20190071423-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20190071419-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20190071421-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2019-03-07 | — | — | US | disclosed |
| US-20190071420-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2019-03-07 | — | — | US | disclosed |
| US-10221178-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| WO-2019038717-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183934-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20190016693-A1 | 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-01-17 | — | — | US | disclosed |
| US-20190016692-A1 | 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-01-17 | — | — | US | disclosed |
| US-10172837-B2 | Insulin sensitisers and methods of treatment | NAIA Metabolic, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-2629777-B1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180346485-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2018-12-06 | — | — | US | disclosed |
| US-20180346480-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-20180339986-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| US-20180339991-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| WO-2018209239-A1 | POTENT AGELASTATIN DERIVATIVES AS MODULATORS FOR CANCER INVASION AND METASTASIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-11-15 | — | — | WO | disclosed |
| WO-2018200857-A1 | GRAFTED POROUS CYCLODEXTRIN POLYMERIC MATERIAL AND METHODS OF MAKING AND USING SAME | CORNELL UNIVERSITY (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20180312524-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-01 | — | — | US | disclosed |
| US-10112915-B2 | 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3390382-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180297939-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2018-10-18 | — | — | US | disclosed |
| US-10100064-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018175474-A1 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | FORMA THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3377493-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-2920171-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2018136265-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136264-A1 | PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018136890-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | JECURE THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018129557-A1 | INHIBITORS OF NHE-MEDIATED ANTIPORT | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018129552-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| EP-2976339-B1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2018112136-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112140-A1 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180162835-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-06-14 | — | — | US | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2018102366-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-2788000-B1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180141947-A1 | Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180118732-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-03 | — | — | US | disclosed |
| WO-2018081108-A1 | AMIDE COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-03 | — | — | WO | disclosed |
| US-9957265-B2 | N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957264-B2 | Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9938300-B2 | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938281-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9932351-B2 | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3292116-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0]HYDROXAMIC ACIDS AS HDAC INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2018039384-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20180044282-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-02-15 | — | — | US | disclosed |
| WO-2018023081-A1 | 6-PHENYLPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AS ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| EP-3268358-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2976338-B1 | N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2017223349-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-9840491-B2 | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2106260-B1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD (AU) | 2017-12-06 | — | — | EP | disclosed |
| EP-3240790-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240791-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9745253-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-9730940-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME (US) | 2017-08-15 | — | — | US | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-2758377-B1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2017106818-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174718-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2763535-B1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2758389-B1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-9630922-B2 | 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9624216-B2 | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170079960-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | NAIA Metabolic, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-9493441-B2 | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2016171756-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311818-A1 | QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2016168660-A1 | 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168598-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304462-A1 | 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | Valo Health, LLC | 2016-10-20 | — | — | US | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160280704-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | US | disclosed |
| EP-3071205-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | Forma Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-3071203-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | Forma Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9452148-B2 | Insulin sensitisers and methods of treatment | VERVA PHARMACEUTICALS LTD (AU) | 2016-09-27 | — | — | US | disclosed |
| US-20160272632-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2016149099-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272633-A1 | N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272634-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160264518-A1 | ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS | Valo Health, LLC | 2016-09-15 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-2758050-B1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9422281-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160229872-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016126722-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126724-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126935-A1 | ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126926-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126721-A1 | 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126726-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126929-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126725-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229864-A1 | THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229833-A1 | QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160222022-A1 | 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160222028-A1 | 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221973-A1 | 3-ARYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160221997-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160207926-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2016109515-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109480-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | disclosed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2976339-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2976341-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2976338-A1 | N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2976340-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150353552-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC | 2015-12-10 | — | — | US | disclosed |
| EP-2920172-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20150232465-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-9096598-B2 | Azaindoles as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015074064-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015074081-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8962608-B2 | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140303142-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-09 | — | — | US | disclosed |
| WO-2014146246-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146249-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146493-A1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146490-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146491-A1 | GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146492-A1 | N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140243309-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | INTERVET INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140228358-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| WO-2014075393-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| EP-2629777-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8455432-B2 | Insulin sensitisers and methods of treatment | VERVA PHARMACEUTICALS LTD. (AU) | 2013-06-04 | — | — | US | disclosed |
| EP-2496576-A1 | IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012054364-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110003740-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD. (AU) | 2011-01-06 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-2106260-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | Verva Pharmaceuticals Ltd (AU) | 2009-10-07 | — | — | EP | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20090105491-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
| WO-2008089521-A1 | INSULIN SENSITISERS AND METHODS OF TREATMENT | VERVA PHARMACEUTICALS LTD (AU) | 2008-07-31 | — | — | WO | disclosed |
| EP-1925611-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1768957-A2 | INDOLE-2-CARBOXYLIC ACID HYDRAZIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | Prosidion Ltd. (GB) | 2007-04-04 | — | — | EP | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005085194-A2 | INDOLE-2-CARBOXYLIC ACID HYDRAZIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PROSIDION LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |